GermanyGermany

Rituximab combination therapy improves progression-free survival in patients with CLL

01.10.2010

Colgne/Basel - Addition of Roche's monoclonal anti-CD20 antibody rituximab to first-line chemotherapy with fludarabine plus cyclophosphamide has improved therapy outcome in patients with chronic lymphocytic leukaemia (CLL) compared with standard chemotherapy alone (Lancet, Cancer Special Issue). In a Phase III trial, 817 therapy-native patients with CLL, that were assigned in a one-to-one ratio to recieve 6 courses of intravenous fludarabine (25 mg/m3.d) and cyclophosphamide (250 mg/m3.d) for the first 3 days of a 28 day treatment course with or without rituximab (375 mg/m3,d on day 0 of 1st course, and 500 mg/m3 on day 1 of the following 5 courses). While 65% of the rituximab group were progression-free at 3 years after randomisation compared to 45% in the chemotherapy only group, the researchers headed by Professor Michael Hallek at University of Cologne observed no significant benefit in overall survival. 87% vs 83% were alive at that point in time. However the risk for leukocytoopenia was 24% vs 12% in the rituximab vs chemotherapy-only group. Additionally, the risk for severe (grade 3-4) neutropenia was higher on rituximab (136 vs 83 patients). CLL is the second most common type of leukaemia. Typically, chemotherapy has been used to treat CLL, but there is currently no treatment available that improves overall survival. Interestingly, improvement in outcome was not uniform across all clinical and genetic subgroups. In particular, patients with chromosome 17p deletion (or p53 dysfunctional CLL) had a poor response, with fewer than 5% achieving complete remission even with chemoimmunotherapy treatment. By contrast, the rate of complete remission increased by more than three times with chemoimmunotherapy in patients with chromosome 11q deletion, a group considered to have a poor prognosis.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/rituximab-combination-therapy-improves-progression-free-survival-in-patients-with-cll.html

Product of the week

Products

Events

All Events

Current issue

All issues